Regenerative medicine technologies rely heavily on the use of well‐designed biomaterials
for therapeutic applications. The success of implantable biomaterials hinges upon the ability …

Background The role of drug‐coated balloons (DCBs) in the treatment of de novo coronary
lesions is not well established. Methods and Results Electronic databases and major …

Bioresorbable scaffolds (BRS) have been advocated as the 'fourth revolution'in
interventional cardiology because they could provide temporary scaffolding and then …

To overcome the limitations of metallic stents, the development of the bioresorbable vascular
scaffold started about 30 years ago. Researchers anticipated a transformative revolution …

Rheumatoid arthritis (RA) is a long-term autoimmune disease. As nanotechnology has
advanced, a growing number of nanodrugs have been used in the treatment of RA due to …

Background Drug-eluting balloons (DEB) have significant value for treating coronary artery
disease (CAD). However, the merits of using DEB versus drug-eluting stents (DES) to treat …

Objectives This prospective, patient‐level analysis assessed the safety and efficacy of
NeoVas sirolimus‐eluting bioresorbable scaffold (BRS) in patients with coronary lesions …

The issue of small coronary artery atherosclerosis represents an intriguing aspect of
coronary artery disease, which is related with higher rates of peri-and post-procedural …

Background: The long-term efficacy and safety of bioresorbable vascular scaffolds (BVS) in
real world clinical practice including Magmaris need to be elucidated to better understand …

Background Bioresorbable Vascular Scaffolds (BVS) were introduced to overcome some of
the limitations of drug-eluting stent (DES) for PCI. Data regarding the clinical outcomes of the …